The goals of Epilepsy Benchmark Area III involve identifying areas that are ripe for progress in terms of controlling seizures and patient symptoms in light of the most recent advances in both basic and clinical research. These goals were developed with an emphasis on potential new therapeutic strategies that will reduce seizure burden and improve quality of life for patients with epilepsy. In particular, we continue to support the proposition that a better understanding of how seizures are initiated, propagated, and terminated in different forms of epilepsy is central to enabling new approaches to treatment, including pharmacological as well as surgical and device-oriented approaches. The stubbornly high rate of treatment-resistant epilepsy-one-third of patients-emphasizes the urgent need for new therapeutic strategies, including pharmacological, procedural, device linked, and genetic. The development of new approaches can be advanced by better animal models of seizure initiation that represent salient features of human epilepsy, as well as humanized models such as induced pluripotent stem cells and organoids. The rapid advances in genetic understanding of a subset of epilepsies provide a path to new and direct patient-relevant cellular and animal models, which could catalyze conceptualization of new treatments that may be broadly applicable across multiple forms of epilepsies beyond those arising from variation in a single gene. Remarkable advances in machine learning algorithms and miniaturization of devices and increases in computational power together provide an enhanced opportunity to detect and mitigate seizures in real time via devices that interrupt electrical activity directly or administer effective pharmaceuticals. Each of these potential areas for advance will be discussed in turn.

中文翻译：

---

癫痫治疗基准区域III：改善的治疗选择，可控制癫痫发作和与癫痫相关的疾病，且无副作用。

癫痫基准研究领域III的目标涉及根据基础研究和临床研究的最新进展，在控制癫痫发作和患者症状方面确定成熟的领域。在制定这些目标时，重点放在可能减轻癫痫发作负担并改善癫痫患者生活质量的潜在新治疗策略上。特别是，我们继续支持这样的主张，即更好地了解癫痫是如何以不同形式的癫痫发作，传播和终止的，这对于启用新的治疗方法（包括药理学以及外科和面向设备的方法）至关重要。顽固性癫痫的治疗率居高不下，占三分之一的患者强调了对新治疗策略（包括药理学，程序，设备链接和遗传。更好的癫痫发作动物模型（代表人类癫痫的主要特征）以及人源化模型（例如诱导的多能干细胞和类器官）可以促进新方法的开发。对癫痫病的子代的遗传学理解的迅速发展为新的和直接的与患者相关的细胞和动物模型提供了一条途径，这可以催化新疗法的概念化，这些新疗法可能广泛适用于多种形式的癫痫病，而不仅仅是因变异引起的癫痫病。单基因。机器学习算法的显着进步和设备的小型化以及计算能力的提高共同为通过直接中断电活动或管理有效药物的设备实时检测和减轻癫痫发作提供了增强的机会。这些潜在的发展领域将依次进行讨论。